nct_id,title,phase,status,study_type,conditions,interventions,molecular_targets,sponsor,collaborators,enrollment_count,start_date,completion_date,locations,needs_review,source_url
NCT00001532,Role of Genetic Factors in the Pathogenesis of Lung Disease,,Recruiting,Observational,Cystic Fibrosis; Pulmonary Fibrosis; Tuberous Sclerosis; Asthma; Pulmonary Sarcoidosis,,,"National Heart, Lung, and Blood Institute (NHLBI)",Suburban Hospital,3500,1996-09-13,,United States,No,https://clinicaltrials.gov/study/NCT00001532
NCT01174121,"A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab",Phase 2,Recruiting,Interventional,Metastatic Colorectal Cancer; Metastatic Pancreatic Cancer; Metastatic Ovarian Cancer; Metastatic Breast Carcinoma; Metastatic Endocrine Tumors/ Neuroendocrine Tumors,Pembrolizumab (Keytruda); Fludarabine; Cyclophosphamide; Aldesleukin; Young TIL,,National Cancer Institute (NCI),,332,2010-08-26,2029-12-27,United States,No,https://clinicaltrials.gov/study/NCT01174121
NCT02012699,Integrated Cancer Repository for Cancer Research,,Recruiting,Observational,Pancreatic Cancer; Thyroid Cancer; Lung Cancer; Esophageal Cancer; Thymus Cancer; Colon Cancer; Rectal Cancer; Gastrointestinal Stromal Tumors; Anal Cancer; Bile Duct Cancer; Duodenal Cancer; Gallbladder Cancer; Gastric Cancer; Liver Cancer; Small Intestine Cancer; Peritoneal Surface Malignancies; Familial Adenomatous Polyposis; Lynch Syndrome; Bladder Cancer; Kidney Cancer; Penile Cancer; Prostate Cancer; Testicular Cancer; Ureter Cancer; Urethral Cancer; Hypopharyngeal Cancer; Laryngeal Cancer; Lip Cancer; Oral Cavity Cancer; Nasopharyngeal Cancer; Oropharyngeal Cancer; Paranasal Sinus Cancer; Nasal Cavity Cancer; Salivary Gland Cancer; Skin Cancer; Central Nervous System Tumor; Central Nervous System Cancer; Mesothelioma; Breast Cancer; Leukemia; Melanoma; Sarcoma; Unknown Primary Tumor; Multiple Myeloma; Ovarian Cancer; Endometrial Cancer; Vaginal Cancer; Neuroendocrine Tumors; Plasma Cell Dyscrasia; Healthy Control,,,University of Nebraska,,999999,2013-11-01,2099-12-05,United States,No,https://clinicaltrials.gov/study/NCT02012699
NCT02417740,Natural History of Noncirrhotic Portal Hypertension,,Recruiting,Observational,Cystic Fibrosis; Immunologic Deficiency Syndrome; Turner Syndrome; Congenital Hepatic Fibrosis; Idiopathic Non-Cirrhotic Portal Hypertension,,,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),,400,2015-07-27,2029-09-04,United States,No,https://clinicaltrials.gov/study/NCT02417740
NCT02757859,The WASH Trial: A Randomized Trial of Abdominal Lavage Using Distilled Water or Saline at High Volumes for Resected Pancreatic Cancer,Not Applicable,Recruiting,Interventional,Acinar Cell Carcinoma; Ampulla of Vater Adenocarcinoma; Cholangiocarcinoma; Duodenal Adenocarcinoma; Pancreatic Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary Mucinous Neoplasm; Periampullary Adenocarcinoma,Pancreatectomy; Lavage; Pancreatectomy; Lavage; Pancreatectomy,,Sidney Kimmel Cancer Center at Thomas Jefferson University,,845,2016-04-27,2026-04-27,United States,No,https://clinicaltrials.gov/study/NCT02757859
NCT03257033,Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer,Phase 3,Recruiting,Interventional,Locally Advanced Pancreatic Cancer,Gemcitabine; nab-paclitaxel; RenovoCath,,RenovoRx,,190,2018-03-12,2026-09-05,Belgium; United States,No,https://clinicaltrials.gov/study/NCT03257033
NCT03551951,"Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers and Subjects Undergoing Lung Cancer Screening",,Recruiting,Observational,Non Small Cell Lung Cancer; Esophageal Cancer; Gastric Cancer; Pancreatic Cancer; Hepatocellular Cancer; Colorectal Cancer,"Test for circulating tumor cells, DNA alterations",,University of Missouri-Columbia,Harry S. Truman Memorial Veterans' Hospital,320,2016-07-01,2027-12-30,United States,No,https://clinicaltrials.gov/study/NCT03551951
NCT03568630,A Longitudinal Cohort Study to Identify Clinical and Blood Markers of Early Pancreas Cancer,,Recruiting,Observational,"Diabetes Mellitus, Type 2; PreDiabetes; Pancreas Cyst; Chronic Pancreatitis; Genetic Predisposition to Disease; Inherited Disease",,,University of Nebraska,National Cancer Institute (NCI); Virginia Mason Hospital/Medical Center; VA Nebraska Western Iowa Health Care System,1250,2018-07-26,2028-07-05,United States,No,https://clinicaltrials.gov/study/NCT03568630
NCT03608631,Phase I Study of Mesenchymal Stromal Cells-Derived Exosomes With KrasG12D siRNA for Metastatic Pancreas Cancer Patients Harboring KrasG12D Mutation,Phase 1/Phase 2,Recruiting,Interventional,KRAS NP_004976.2:p.G12D; Metastatic Pancreatic Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8,Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA,,M.D. Anderson Cancer Center,,28,2021-01-27,2027-04-30,United States,No,https://clinicaltrials.gov/study/NCT03608631
NCT03740256,A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors,Phase 1,Recruiting,Interventional,Bladder Cancer; Head and Neck Squamous Cell Carcinoma; Cancer of the Salivary Gland; Lung Cancer; Breast Cancer; Gastric Cancer; Esophageal Cancer; Colorectal Cancer; Pancreatic Adenocarcinoma; Solid Tumor,CAdVEC,,Baylor College of Medicine,The Methodist Hospital Research Institute,45,2020-12-14,2038-12-30,United States,No,https://clinicaltrials.gov/study/NCT03740256
NCT03745326,A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients,Phase 1/Phase 2,Recruiting,Interventional,Gastrointestinal Cancer; Pancreatic Cancer; Gastric Cancer; Colon Cancer; Rectal Cancer,Cyclophosphamide; Fludarabine; Aldesleukin; anti-KRAS G12D mTCR PBL,,National Cancer Institute (NCI),,70,2019-05-16,2028-12-01,United States,No,https://clinicaltrials.gov/study/NCT03745326
NCT04157127,Phase I Study of Th-1 Dendritic Cell Immunotherapy in Combination With Standard Chemotherapy for the Adjuvant Treatment of Pancreatic Adenocarcinoma (DECIST),Phase 1,Recruiting,Interventional,Pancreatic Adenocarcinoma; Pancreatic Cancer; Pancreatic Adenosquamous Carcinoma,Autologous DC Therapy,,Diakonos Oncology Corporation,Baylor College of Medicine,18,2020-08-03,2027-12-05,United States,No,https://clinicaltrials.gov/study/NCT04157127
NCT04222413,"First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumors; Metastatic Pancreatic Cancer; Pediatric Solid Tumor; Advanced Breast Cancer; Malignant Peripheral Nerve Sheath Tumor; Colorectal Neoplasms,Metarrestin,,National Cancer Institute (NCI),,116,2020-10-27,2028-12-31,United States,No,https://clinicaltrials.gov/study/NCT04222413
NCT04361708,"A Phase 1 Dose Finding Study of the gFOLFOXIRITAX Regimen Using UGT1A1 Genotype-directed Irinotecan With Fluorouracil, Leucovorin, Oxaliplatin and Taxotere in Patients With Untreated Advanced Upper Gastrointestinal Adenocarcinomas: The I-FLOAT Study",Phase 1,Recruiting,Interventional,Pancreatic Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Adenocarcinoma,Oxaliplatin; Docetaxel; Leucovorin; Irinotecan; 5-Fluorouracil,,University of Chicago,,54,2020-05-08,2027-05-05,United States,No,https://clinicaltrials.gov/study/NCT04361708
NCT04404101,Evaluation of Pancreatic Cystic Lesions Via EUS-Guided Fine Needle Aspiration With and Without Micro Forceps Biopsies: A Multi-Center Prospective Randomized Study,Not Applicable,Recruiting,Interventional,Pancreatic Cyst,1). EUS-FNA plus MFB; 2). EUS-FNA Alone,,"University of Colorado, Denver",US Endoscopy,300,2021-05-11,2025-04-05,United States,No,https://clinicaltrials.gov/study/NCT04404101
NCT04484909,Phase I Study of NBTXR3 Activated by Radiotherapy for Locally Advanced or Borderline Resectable Pancreatic Ductal Adenocarcinoma,Phase 1,Recruiting,Interventional,Borderline Resectable Pancreatic Adenocarcinoma; Locally Advanced Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Ductal Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8,Hafnium Oxide-containing Nanoparticles NBTXR3; Radiation Therapy,,M.D. Anderson Cancer Center,National Cancer Institute (NCI),24,2020-07-01,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT04484909
NCT04609592,"Pilot Phase 1 Study of Perioperative Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic, WHO Grade 1 or 2, SSTR Positive, Gastroenteropancreatic Neuroendocrine Tumors Who Are Candidates for Cytoreductive Surgery",Phase 1,Recruiting,Interventional,Gastroenteropancreatic Neuroendocrine Tumor,Lutathera; Gallium 68 Dotatate; Computed Tomography (CT); Magnetic Resonance Imaging (MRI); PET/CT,,Stanford University,Novartis Pharmaceuticals,10,2021-03-17,2027-09-05,United States,No,https://clinicaltrials.gov/study/NCT04609592
NCT04657068,"A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Advanced Cancer; Metastatic Cancer; Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer; Endometrial Cancer; Metastatic Colorectal Cancer; Pancreatic Ductal Adenocarcinoma; Acinar Cell Carcinoma,ART0380; Gemcitabine; Irinotecan,,Artios Pharma Ltd,,502,2020-12-13,2026-12-05,France; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04657068
NCT04789486,Nano-SMART: An Adaptive Phase I-II Trial of AGuIX Gadolinium-based Nanoparticles With Stereotactic Magnetic Resonance-guided Adaptive Radiation Therapy for Centrally Located Lung Tumors and Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma,Phase 1/Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer; Advanced Pancreatic Adenocarcinoma; Unresectable Pancreatic Cancer; Ductal Adenocarcinoma of the Pancreas,AGuIX; Radiotherapy,,Dana-Farber Cancer Institute,NH TherAguix SAS,100,2021-05-27,2027-09-10,United States,No,https://clinicaltrials.gov/study/NCT04789486
NCT04820179,"Phase II Trial Evaluating the Safety and Efficacy of Atezolizumab in Combination With Cabozantinib for the Treatment of Metastatic, Refractory Pancreatic Cancer",Phase 2,Recruiting,Interventional,Pancreatic Cancer; Metastatic Pancreatic Cancer,Cabozantinib + Atezolizumab,,University of Arizona,,29,2021-10-12,2026-01-31,United States,No,https://clinicaltrials.gov/study/NCT04820179
NCT04887805,Phase II Trial of Lenvatinib-Pembrolizumab Maintenance Therapy in Patients With Advanced Unresectable Pancreatic Cancer,Phase 2,Recruiting,Interventional,Advanced Pancreatic Ductal Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage IIA Pancreatic Cancer AJCC v8; Stage IIB Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Ductal Adenocarcinoma,Lenvatinib Mesylate; Pembrolizumab,,City of Hope Medical Center,National Cancer Institute (NCI),28,2021-07-21,2026-11-05,United States,No,https://clinicaltrials.gov/study/NCT04887805
NCT04939610,"LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumor",Phase 1/Phase 2,Recruiting,Interventional,Solid Tumor,68Ga-FAP-2286; 177Lu-FAP-2286,,Novartis Pharmaceuticals,,222,2021-07-30,2028-06-30,Australia; Canada; France; Italy; United States,No,https://clinicaltrials.gov/study/NCT04939610
NCT04970056,Pancreatic Cancer Early Detection Consortium,,Recruiting,Observational,Pancreas Cancer; Pancreas Cyst; Pancreatic Ductal Adenocarcinoma; Genetic Predisposition,,,Arbor Research Collaborative for Health,,10000,2020-09-18,2030-12-31,Australia; Canada; Hungary; Iceland; Israel; Italy; Singapore; Spain; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04970056
NCT05086250,"A Prospective, Single Center, Double Blind, Randomized, Crossover Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer",Early Phase 1,Recruiting,Interventional,Anxiety; Pancreatic Cancer,Ketamine; Placebo; Placebo; Ketamine,,Cedars-Sinai Medical Center,,20,2022-10-20,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT05086250
NCT05141149,"A First in Human, Phase 1/2a, Multicentre, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of PBP1510 in Patients With Advanced/Metastatic Pancreatic Cancer",Phase 1/Phase 2,Recruiting,Interventional,Pancreatic Cancer,PBP1510 (400mg/16mL); Gemcitabine (1000 mg/m^2),,Prestige Biopharma Limited,,80,2023-06-05,2026-12-05,Australia; Singapore; Spain; United States,No,https://clinicaltrials.gov/study/NCT05141149
NCT05254184,Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Advanced KRAS Mutated Non-Small Cell Lung Cancer,Phase 1,Recruiting,Interventional,Non-Small Cell Lung Cancer,Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides,,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,12,2022-11-01,2027-04-01,United States,No,https://clinicaltrials.gov/study/NCT05254184
NCT05296421,Pilot Study to Investigate Targetable Metabolic Pathways Sustaining Pancreatic Cancer and Associated Genomic Alterations,Not Applicable,Recruiting,Interventional,Pancreatic Ductal Adenocarcinoma,Biopsy; Therapeutic Conventional Surgery; Uniformly-labeled [13C]glucose,,"Rutgers, The State University of New Jersey",National Cancer Institute (NCI),16,2022-03-14,2026-07-01,United States,No,https://clinicaltrials.gov/study/NCT05296421
NCT05382559,A Phase 1 Study of ASP3082 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation,Phase 1,Recruiting,Interventional,Solid Tumor,ASP3082; Cetuximab; Leucovorin; Oxaplatin; Fluorouracil; Irinotecan; Nanoparticle albumin-bound-paclitaxel; Gemcitabine; Docetaxel; Pembrolizumab; Cisplatin; Carboplatin; Pemetrexed,,Astellas Pharma Inc,,651,2022-06-08,2026-10-31,China; France; Japan; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT05382559
NCT05535894,Endoscopic Ultrasound-guided Radiofrequency Ablation of Celiac Ganglion for Pain Management and Improvement of Quality of Life in Patients With Unresectable Pancreatic Cancer,,Recruiting,Observational,Pancreatic Cancer,Ablation of Celiac Ganglion,,West Virginia University,,12,2022-08-10,2025-12-05,United States,No,https://clinicaltrials.gov/study/NCT05535894
NCT05625529,Exoluminate Study: Observational Registry Study to Assess Exo-PDAC Assay Performance for Detection of Pancreatic Adenocarcinoma (PDAC) in High-Risk or Clinically Suspicious Patients,,Recruiting,Observational,Pancreas Cancer; Exosomes; Extracellular Vesicles; Pancreatic Neoplasms,,,Biological Dynamics,,1000,2022-12-19,2028-01-01,United States,No,https://clinicaltrials.gov/study/NCT05625529
NCT05688215,A Pilot Study of Zimberelimab and Quemliclustat Combination With Chemotherapy in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma,Phase 1/Phase 2,Recruiting,Interventional,Borderline Resectable Pancreatic Adenocarcinoma; Locally Advanced Pancreatic Ductal Adenocarcinoma,Biospecimen Collection; Computed Tomography; Core Biopsy; Fluorouracil; Irinotecan; Leucovorin; Leucovorin Calcium; Oxaliplatin; Quemliclustat; Zimberelimab,,Jonsson Comprehensive Cancer Center,"Arcus Biosciences, Inc.",56,2023-03-07,2026-03-02,United States,No,https://clinicaltrials.gov/study/NCT05688215
NCT05694715,Combination Therapy of Niraparib and Irinotecan in Cancers With Mutations in DNA Repair Genes,Phase 1,Recruiting,Interventional,Metastatic Solid Tumor; BRCA1 Mutation; BRCA2 Mutation; ATM Gene Mutation; PALB2 Gene Mutation,Niraparib; Irinotecan,,"University of California, San Francisco",GlaxoSmithKline,24,2023-05-23,2028-01-31,United States,No,https://clinicaltrials.gov/study/NCT05694715
NCT05786924,"A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies",Phase 1/Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer; Histiocytic Neoplasm; Histiocytosis; BRAF Gene Mutation; BRAF V600E; BRAF V600 Mutation; BRAF Mutation-Related Tumors; BRAF; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Lung Cancer; Recurrent Lung Cancer; Recurrent Lung Non-Small Cell Carcinoma; NSCLC; Solid Tumor; Solid Carcinoma; KRAS G12D; KRAS G12V; KRAS Mutation-Related Tumors; NRAS Gene Mutation; Thyroid Cancer; Thyroid Carcinoma; Colorectal Cancer; Colorectal Carcinoma; Recurrent Histiocytic and Dendritic Cell Neoplasm; Brain Metastases; Recurrent NSCLC; KRAS G13C; Acquired Resistance to KRAS G12C Inhibitor; KRAS G12A; KRAS G12F; KRAS G12R; KRAS G13D,S241656; FOLFOX6/FOLFOX7; FOLFIRI; Cetuximab; Panitumumab; Gemcitabine; Nab-paclitaxel,,Institut de Recherches Internationales Servier,,554,2023-04-18,2028-06-05,United States,No,https://clinicaltrials.gov/study/NCT05786924
NCT05799274,Characterizing the Radiochemical and Radiation Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Ductal Adenocarcinoma or Other Solid Tumors,Phase 1,Recruiting,Interventional,Healthy Volunteers; Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer (NSCLC); Esophageal Squamous Cell Carcinoma; Cervical Cancer; Endometrial Cancer; Ovarian Cancer,RAD301 ([68Ga]-RAD301),,"Radiopharm Theranostics, Ltd",,9,2023-11-09,2025-11-05,United States,No,https://clinicaltrials.gov/study/NCT05799274
NCT05836870,Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer,Phase 3,Recruiting,Interventional,Pancreatic Cancer,Enhanced Usual Care; Tele-supervised resistance exercises,,M.D. Anderson Cancer Center,,120,2023-07-18,2032-12-31,United States,No,https://clinicaltrials.gov/study/NCT05836870
NCT05983133,A Phase 1 Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors,Phase 1,Recruiting,Interventional,"Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Squamous Cell Carcinoma of the Head and Neck; Pancreatic Ductal Adenocarcinoma",PF-08046052,,"Seagen, a wholly owned subsidiary of Pfizer",,290,2023-11-14,2030-01-09,United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05983133
NCT05984602,A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer,Phase 1,Recruiting,Interventional,Pancreatic Cancer,Canakinumab; Tislelizumab; Nab-Paclitaxel; Gemcitabine,,NYU Langone Health,,10,2023-07-14,2026-01-01,United States,No,https://clinicaltrials.gov/study/NCT05984602
NCT05985655,"A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,"Advanced Solid Tumor; Head and Neck Squamous Cell Carcinoma (HNSCC); Pancreatic Adenocarcinoma; Non-small Cell Lung Cancer (NSCLC); Breast Carcinoma; High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC); Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma",GTAEXS617; SoC,,"Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.",,165,2023-07-06,2028-05-05,Belgium; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05985655
NCT05997056,"A Phase 2 Multi-center, Open-label, Single Arm Study of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors",Phase 2,Recruiting,Interventional,Neuroendocrine Tumors; NET; Pancreatic Neuroendocrine Tumor; Gastrointestinal Neuroendocrine Tumor; Pulmonary Neuroendocrine Tumor,nab-sirolimus,,"Aadi Bioscience, Inc.",,21,2023-11-07,2025-12-08,United States,No,https://clinicaltrials.gov/study/NCT05997056
NCT06026410,"Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Solid Tumors With HRAS Alterations; Non Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Clear Cell Renal Cell Carcinoma (ccRCC); Renal Cell Carcinoma (Kidney Cancer); Non Clear Cell Renal Cell Carcinoma (nccRCC),Darlifarnib; Cabozantinib; Adagrasib,,"Kura Oncology, Inc.",Mirati Therapeutics Inc.,300,2023-10-18,2027-04-05,France; Italy; Spain; United States,No,https://clinicaltrials.gov/study/NCT06026410
NCT06037837,Generalized Robotic Skills Assessment Using Machine Learning-Based Analysis Across Multiple Surgical Specialties,,Enrolling by invitation,Observational,Surgery,Robotic Surgery,,Memorial Sloan Kettering Cancer Center,,1000,2023-08-24,2026-08-24,United States,No,https://clinicaltrials.gov/study/NCT06037837
NCT06040541,"Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG 12D-Mutant Solid Tumors",Phase 1,Recruiting,Interventional,Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Advanced Solid Tumors,RMC-9805; RMC-6236,,"Revolution Medicines, Inc.",,604,2023-09-07,2027-04-30,United States,No,https://clinicaltrials.gov/study/NCT06040541
NCT06048484,"A Phase 2, Open-Label, Multicenter, Randomized Study Evaluating Neoadjuvant Therapy Targeting the Adenosine Immunosuppressive Pathway in Combination With Immune Checkpoint Blockade and Radiation Therapy in Patients With Advanced PANCreatic Ductal Adenocarcinoma Who Are Candidates for Surgical Resection",Phase 2,Recruiting,Interventional,Pancreatic Ductal Adenocarcinoma,Stereotactic body radiotherapy (SBRT); Zimberelimab; Quemliclustat; Etrumadenant; Modified FOLFIRINOX,,Gulam Manji,"Arcus Biosciences, Inc.",60,2024-05-10,2027-04-05,United States,No,https://clinicaltrials.gov/study/NCT06048484
NCT06122480,Surgical Resection of Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma (PHOLIPANC): A Phase II Single Arm Trial,Not Applicable,Recruiting,Interventional,Pancreatic Ductal Adenocarcinoma; Oligometastatic Disease,Surgery,,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,40,2024-05-21,2028-04-01,United States,No,https://clinicaltrials.gov/study/NCT06122480
NCT06131840,An Open-label Phase 1 Study to Investigate PF-08046050 (SGN-CEACAM5C) in Adults With Advanced Solid Tumors,Phase 1,Recruiting,Interventional,"Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Stomach Neoplasms; Pancreatic Ductal Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Small Cell Lung Carcinoma",PF-08046050; bevacizumab; 5-Fluorouracil (5-FU); Oxaliplatin; Leucovorin (LV),,"Seagen, a wholly owned subsidiary of Pfizer",Sanofi,914,2023-11-20,2030-09-12,Canada; France; Netherlands; Spain; Sweden; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06131840
NCT06158139,A Phase I Study of Autologous CAR-T Cells Targeting the B7-H3 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects With Refractory Pancreatic Ductal Adenocarcinoma (PDAC),Phase 1,Recruiting,Interventional,Pancreas Cancer; Relapse; Resistant Cancer,iC9-CAR.B7-H3 T cell infusion,,UNC Lineberger Comprehensive Cancer Center,M.D. Anderson Cancer Center,27,2024-07-18,2028-06-05,United States,No,https://clinicaltrials.gov/study/NCT06158139
NCT06162221,A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC),Phase 1/Phase 2,Recruiting,Interventional,"Non-Small Cell Lung Cancer, NSCLC; KRAS, NRAS, HRAS-mutated NSCLC; KRAS G12C-mutated Solid Tumors, Lung Cancer; Lung Cancer Stage IV, Advanced Solid Tumor, Cancer; RAS G12D-mutated NSCLC",RMC-6291; RMC-6236; Pembrolizumab; Cisplatin; Carboplatin; Pemetrexed; RMC-9805,,"Revolution Medicines, Inc.",,616,2024-01-18,2028-12-05,Australia; Denmark; France; Germany; Greece; Italy; Netherlands; Spain; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06162221
NCT06179160,"A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation",Phase 1,Recruiting,Interventional,Solid Tumors,INCB161734; Cetuximab; Retifanlimab; GEMNabP; mFOLFIRINOX; FOLFOX; FOLFIRI; INCA33890,,Incyte Corporation,,710,2024-01-04,2027-01-01,Australia; Belgium; Canada; France; Italy; Japan; Spain; United States,No,https://clinicaltrials.gov/study/NCT06179160
NCT06182072,"A Phase I/Ib Trial of ProAgio, an Anti- αvβ3 Integrin Cytotoxin, in Combination With Gemcitabine and Nab-paclitaxel or Gemcitabine, Nab-paclitaxel and Atezolizumab for Advanced Pancreatic Cancer",Phase 1,Recruiting,Interventional,Pancreatic Ductal Adenocarcinoma (PDAC),"ProAgio Dose Levels (DL) 1,2,3,4; Gemcitabine, nab paclitaxel",,"ProDa BioTech, LLC",University of Alabama at Birmingham; Georgia State University,46,2023-09-14,2028-06-30,United States,No,https://clinicaltrials.gov/study/NCT06182072
NCT06218914,"Open-label, Phase 1, Multi-Center Master Protocol to Evaluate the Safety and Preliminary Anti-Tumor Activity of TCR-engineered T Cells Recognizing KRAS Mutations in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors",Phase 1,Recruiting,Interventional,"Non-small Cell Lung Cancer; Colorectal Carcinoma; Pancreatic Ductal Adenocarcinoma; Endometrial Cancer; Solid Tumor, Adult; KRAS G12D","NT-112: Autologous, engineered T Cells targeting KRAS G12D; AZD0240: Autologous, engineered T Cells targeting KRAS G12D",,AstraZeneca,,24,2024-03-22,2043-11-18,United States,No,https://clinicaltrials.gov/study/NCT06218914
NCT06227377,"A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients With Solid Tumors With KRASG12D Mutation",Phase 1,Recruiting,Interventional,Solid Tumors,QTX3034; Cetuximab,,Quanta Therapeutics,,250,2024-02-05,2027-04-01,United States,No,https://clinicaltrials.gov/study/NCT06227377
NCT06271291,Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts,,Recruiting,Observational,Pancreatic Carcinoma,Non-Interventional Study,,Mayo Clinic,National Cancer Institute (NCI),30000,2024-12-12,2029-11-01,United States,No,https://clinicaltrials.gov/study/NCT06271291
NCT06276764,The LINFU® U.S. Registry for the Detection of Dysplasia and Pancreatic Ductal Adenocarcinoma (PDAC) in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas),,Enrolling by invitation,Observational,"IPMN, Pancreatic; Pancreas Cancer; Pancreatic Cyst",LINFU®,,"Adenocyte, LLC",,500,2024-10-15,2034-12-01,United States,No,https://clinicaltrials.gov/study/NCT06276764
NCT06360354,"A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion",Phase 1,Recruiting,Interventional,"Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers",AMG 193; Gemcitabine; Nab-paclitaxel; Modified FOLFIRINOX; RMC-6236,,Amgen,,350,2024-05-29,2029-02-25,Australia; Belgium; Canada; China; Denmark; France; Germany; Greece; Hong Kong; Italy; Japan; Netherlands; Spain; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06360354
NCT06364696,An Open-label Phase 1 Study of ASP4396 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation,Phase 1,Recruiting,Interventional,Solid Tumor,ASP4396,,Astellas Pharma Inc,,175,2024-04-16,2027-04-30,United States,No,https://clinicaltrials.gov/study/NCT06364696
NCT06385925,Phase 1/2 Study of TSN1611 in Subjects With Advanced Solid Tumors Harboring KRAS G12D Mutation,Phase 1/Phase 2,Recruiting,Interventional,Malignant Neoplasm,TSN1611; TSN1611; TSN1611; TSN1611,,Tyligand Pharmaceuticals (Suzhou) Limited,,440,2024-04-29,2027-04-30,China; United States,No,https://clinicaltrials.gov/study/NCT06385925
NCT06411691,Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Adenocarcinoma,Phase 1,Recruiting,Interventional,Colorectal Cancer; Pancreatic Cancer,KRAS Vaccine with Poly-ICLC adjuvant; Balstilimab; Botensilimab,,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Agenus Inc.; Private Philanthropic Funds; National Cancer Institute (NCI); United States Department of Defense,54,2025-06-24,2029-07-01,United States,No,https://clinicaltrials.gov/study/NCT06411691
NCT06445062,A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors,Phase 1/Phase 2,Recruiting,Interventional,Colorectal Cancer; CRC; Pancreatic Ductal Adenocarcinoma; PDAC; Gastrointestinal Cancer; Metastatic Pancreatic Ductal Adenocarcinoma,RMC-6236; mFOLFOX6 regimen; bevacizumab; mFOLFIRINOX regimen; cetuximab; gemcitabine; nab-paclitaxel; RMC-9805,,"Revolution Medicines, Inc.",,1130,2024-05-24,2027-07-15,United States,No,https://clinicaltrials.gov/study/NCT06445062
NCT06447662,A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene,Phase 1,Recruiting,Interventional,"Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung",PF-07934040; Gemcitabine; Nab-paclitaxel; Cetuximab; Fluorouracil; Oxaliplatin; Leucovorin; Bevacizumab; Pembrolizumab; pemetrexed; Cisplatin; Paclitaxel; Carboplatin,,Pfizer,,330,2024-06-27,2028-09-09,Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT06447662
NCT06454383,A Phase 1b Study of Gemcitabine and Leflunomide in Patients With Unresectable Pancreatic Cancer,Phase 1,Recruiting,Interventional,Advanced Pancreatic Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Ductal Adenocarcinoma,Biospecimen Collection; Cholestyramine; Computed Tomography; Diagnostic Imaging; Gemcitabine; Leflunomide; Magnetic Resonance Imaging,,City of Hope Medical Center,National Cancer Institute (NCI),19,2024-05-13,2026-11-13,United States,No,https://clinicaltrials.gov/study/NCT06454383
NCT06562192,"Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers",Phase 1,Recruiting,Interventional,Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; HR+/HER2- Ductal and Lobular Breast Cancer; Triple Negative Breast Cancer; Colorectal Cancer,[68Ga]Ga-NNS309; [177Lu]Lu-NNS309,,Novartis Pharmaceuticals,,162,2024-10-15,2031-01-16,Belgium; Canada; France; Germany; Israel; Italy; Netherlands; Spain; Switzerland; United States,No,https://clinicaltrials.gov/study/NCT06562192
NCT06586515,A Phase 1a/1b Trial of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors,Phase 1,Recruiting,Interventional,Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; Colorectal Cancer,LY3962673; Cetuximab; Gemcitabine; nab-paclitaxel; Oxaliplatin; leucovorin; Irinotecan; 5-fluorouracil,,Eli Lilly and Company,,630,2024-09-12,2029-03-05,Canada; China; France; Germany; Ireland; Italy; Japan; Spain; United States,No,https://clinicaltrials.gov/study/NCT06586515
NCT06607185,A Phase 1a/1b Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors,Phase 1,Recruiting,Interventional,Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; Colorectal Cancer; Advanced Solid Tumor; Metastatic Solid Tumor,LY4066434.; Cetuximab; Nab paclitaxel; Gemcitabine; Oxaliplatin; Leucovorin; Irinotecan; 5Fluorouracil; Carboplatin; Cisplatin; Pemetrexed; Pembrolizumab,,Eli Lilly and Company,,750,2024-10-21,2030-01-05,Belgium; China; France; Germany; Italy; Japan; Spain; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06607185
NCT06619587,"A Phase I/II Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors With a KRAS G12D Mutation",Phase 1,Recruiting,Interventional,Solid Tumor,Phase I Arm A; Phase I Arm B,,"Genentech, Inc.",,410,2024-11-14,2028-05-31,Australia; Canada; Israel; Singapore; South Korea; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06619587
NCT06630325,Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART): Adaptive Clinical Treatment (ACT),Phase 2,Recruiting,Interventional,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8,Abemaciclib; Biopsy; Bone Scan; Carboplatin; Echocardiography; Exemestane; Fulvestrant; Gefitinib; Gemcitabine; Letrozole; Multigated Acquisition Scan; Olaparib; Osimertinib; Paclitaxel; Pegylated Liposomal Doxorubicin Hydrochloride; Pemetrexed; Survey Administration; Tamoxifen; Temozolomide; Biospecimen Collection,,OHSU Knight Cancer Institute,Oregon Health and Science University; Eli Lilly and Company; AstraZeneca,30,2025-06-24,2033-06-30,United States,No,https://clinicaltrials.gov/study/NCT06630325
NCT06663072,A Phase I Study of Fulvestrant in Combination With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors,Phase 1,Recruiting,Interventional,Metastatic Pancreatic Neuroendocrine Tumor,Fulvestrant; 177Lu-DOTATATE,,University of Chicago,,25,2024-12-13,2026-11-05,United States,No,https://clinicaltrials.gov/study/NCT06663072
NCT06698458,A Study to Assess the Safety of Intratumoral Diffusing Alpha Radiation Emitters With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer,Not Applicable,Recruiting,Interventional,Pancreatic Cancer; Pancreatic Adenocarcinoma; Metastatic Pancreatic Cancer,Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT),,Alpha Tau Medical LTD.,,30,2025-06-17,2026-12-05,Canada; Israel; United States,No,https://clinicaltrials.gov/study/NCT06698458
NCT06704724,A PHASE 1 OPEN-LABEL STUDY OF PF-07985045 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS,Phase 1,Recruiting,Interventional,"Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung",PF-07985045; Gemcitabine; Nab-paclitaxel; Cetuximab; Fluorouracil; Oxaliplatin; Leucovorin; Bevacizumab; Pembrolizumab; Sasanlimab; pemetrexed; Cisplatin; Paclitaxel; Carboplatin; PF-07284892,,Pfizer,,190,2024-12-10,2029-03-11,Japan; Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT06704724
NCT06747845,ParpVax2: A Phase II Study Of Maintenance Niraparib Plus Ipilimumab In Patients With Metastatic Pancreatic Cancer Whose Disease Has Not Progressed On Platinum-Based Therapy,Phase 2,Recruiting,Interventional,Pancreatic Adenocarcinoma Metastatic,Niraparib; FOLFIRI; Ipilimumab,,Abramson Cancer Center at Penn Medicine,Lustgarten Foundation; GlaxoSmithKline; Bristol-Myers Squibb,68,2025-05-07,2029-01-30,United States,No,https://clinicaltrials.gov/study/NCT06747845
NCT06790602,"A Single-arm, Open-label, Phase II Trial of Cemiplimab Plus Gemcitabine as Second-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Harboring SWItch/Sucrose Non-Fermentable (SWI/SNF) Alterations.",Phase 2,Not yet recruiting,Interventional,Pancreatic Ductal Adenocarcinoma (mPDAC),Cemiplimab Plus Gemcitabine,,"University of California, San Diego",Regeneron Pharmaceuticals,43,2025-11-05,2029-12-05,United States,No,https://clinicaltrials.gov/study/NCT06790602
NCT06797336,"A Phase 1, Open-Label Dose Escalation and Expansion Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Solid Tumor,PT0253,,"PAQ Therapeutics, Inc.",,115,2024-12-19,2027-06-16,United States,No,https://clinicaltrials.gov/study/NCT06797336
NCT06821997,A Phase 2 Clinical Trial of Nalirifox as Neoadjuvant Treatment for Patients With Borderline Resectable Pancreatic Ductal Adenocarcinoma (Nectar Study),Phase 2,Recruiting,Interventional,Borderline Resectable Pancreatic Ductal Adenocarcinoma,Biospecimen Collection; Computed Tomography; Fluorouracil; Irinotecan Sucrosofate; Leucovorin Calcium; Oxaliplatin; Surgical Procedure,,Roswell Park Cancer Institute,,20,2025-12-01,2027-03-01,United States,No,https://clinicaltrials.gov/study/NCT06821997
NCT06906562,"A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR2 Gene Fusions or Other FGFR Genetic Alterations",Phase 2,Recruiting,Interventional,Advanced Pancreatic Carcinoma; Metastatic Pancreatic Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8,Pemigatinib; Computed Tomography (CT); Magnetic Resonance Imaging; Optical Coherence Tomography; Bone Scan; Ophthalmoscopy,,Sameek Roychowdhury,Incyte Corporation,40,2025-08-26,2028-12-31,United States,No,https://clinicaltrials.gov/study/NCT06906562
NCT06910657,"A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Colorectal Cancer; Pancreatic Cancer; Melanoma; Ovarian Cancer; Gastric Cancer; Esophageal Cancer; Hepatocellular Carcinoma; Renal Cell Carcinoma; Breast Cancer; Sarcoma; Bladder Cancer; Lung Cancer; Prostate Cancer; Cervical Cancers; Head and Neck Cancers; Adrenal Gland Tumors,IDOV-Immune (oncolytic vaccinia virus),,"ViroMissile, Inc.",,78,2025-08-25,2027-05-31,Australia; United States,No,https://clinicaltrials.gov/study/NCT06910657
NCT06917079,"A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers",Phase 1,Recruiting,Interventional,"Non-Small Cell Lung Cancer; NSCLC; PDAC - Pancreatic Ductal Adenocarcinoma; CRC (Colorectal Cancer); Metastatic Non-Small Lung Cell Cancer; Metastatic Colorectal Cancer (CRC); KRAS G12A; KRAS G12C; KRAS G12D; KRAS G12S; KRAS G12V; Metastatic Pancreatic Ductal Adenocarcinoma; Advanced Lung Carcinoma; Solid Tumor, Adult",BBO-11818; Pembrolizumab; Platinum chemotherapy (cisplatin or carboplatin); Pemetrexed; Cetuximab,,"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)",,287,2025-03-31,2029-09-05,United States,No,https://clinicaltrials.gov/study/NCT06917079
NCT06922591,"A Phase 1/2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability & Antitumor Activity of TNG462 in Combination With Other Agents in Patients With Pancreatic Cancer With MTAP Loss and Pancreatic or Non-Small Cell Lung Cancer With MTAP Loss & RAS Mutation",Phase 1/Phase 2,Recruiting,Interventional,PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; NSCLC; RAS Mutation; MTAP Deletion; Lung Cancer; Pancreatic Cancer Metastatic; Thoracic Cancer,TNG462; RMC-9805; RMC-6236; mFOLFIRINOX; gemcitabine/nab-paclitaxel,,"Tango Therapeutics, Inc.","Revolution Medicines, Inc.",183,2025-05-31,2027-12-05,United States,No,https://clinicaltrials.gov/study/NCT06922591
NCT06984562,Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer: Phase I Dose Escalation Study,Not Applicable,Recruiting,Interventional,Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA),Adaptive Radiation Therapy,,Fox Chase Cancer Center,,16,2025-08-20,2029-08-01,United States,No,https://clinicaltrials.gov/study/NCT06984562
NCT06989437,"A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (PF-06946860) Compared With Placebo Both With Background First-Line Chemotherapy in Adult Participants With Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma",Phase 2/Phase 3,Recruiting,Interventional,Cachexia; Metastatic Pancreatic Ductal Adenocarcinoma,ponsegromab; placebo,,Pfizer,,982,2025-10-03,2029-12-23,Australia; Israel; Japan; Puerto Rico; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06989437
NCT06995898,The Vanguard Study: Testing a New Way to Screen for Cancer,Not Applicable,Recruiting,Interventional,Bladder Carcinoma; Breast Carcinoma; Colorectal Carcinoma; Esophageal Carcinoma; Gastric Carcinoma; Liver Carcinoma; Lung Carcinoma; Malignant Solid Neoplasm; Ovarian Carcinoma; Pancreatic Carcinoma; Prostate Carcinoma,Biospecimen Collection; Device Usage; Electronic Health Record Review; Multi-Cancer Detection Test; Multi-Cancer Detection Test; Questionnaire Administration,,National Cancer Institute (NCI),,24000,2025-06-16,2029-06-30,United States,No,https://clinicaltrials.gov/study/NCT06995898
NCT06999187,"A Phase 1a/1b, Multicenter, Open-label, Dose Escalation/Expansion, Multiple-dose Study to Evaluate the Safety and Activity of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas",Phase 1,Recruiting,Interventional,Triple Negative Breast Cancer; HER2-negative Breast Cancer; Non Small Cell Lung Cancer; Cervical Cancer; Castrate Resistant Prostate Cancer; Pancreatic Ductal Adenocarcinoma; Head-and-neck Squamous Cell Carcinoma; Endometrial Cancer; Ovarian Cancer; Gastric Cancer; Gastroesophageal-junction Cancer; Urothelial Carcinoma,DR-0202,,Dren Bio,,96,2025-06-03,2027-12-05,United States,No,https://clinicaltrials.gov/study/NCT06999187
NCT07020221,"A Phase 1/2a, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,"Pancreatic Ductal Adenocarcinoma; Non Small Cell Lung Cancer; Colorectal Cancer; Solid Tumor, Adult; G12D Mutated KRAS",VS-7375; Cetuximab; Carboplatin + Pemetrexed + Pembrolizumab; Gemcitabine; Gemcitabine + Nab-paclitaxel,,"Verastem, Inc.",,330,2025-06-24,2028-09-05,United States,No,https://clinicaltrials.gov/study/NCT07020221
NCT07021066,"A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Advanced or Metastatic Solid Tumors",Phase 1,Recruiting,Interventional,Gastric Adenocarcinoma; Advanced Pancreatic Ductal Adenocarcinoma; Esophageal Adenocarcinoma; Biliary Tract Cancer; Other Solid Tumors,BL-M05D1,,SystImmune Inc.,,120,2025-07-30,2027-05-31,United States,No,https://clinicaltrials.gov/study/NCT07021066
NCT07023731,"A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,KRAS G12D Mutation; Advanced Solid Cancer,ARV-806,,Arvinas Inc.,,159,2025-05-29,2029-04-02,United States,No,https://clinicaltrials.gov/study/NCT07023731
NCT07024615,A Phase 1b Study of Neoadjuvant ASP2138 Monotherapy and Investigator's Choice of Adjuvant Chemotherapy in Participants With Resectable Pancreatic Ductal Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression,Phase 1,Recruiting,Interventional,Pancreatic Ductal Adenocarcinoma,ASP2138; Oxaliplatin; Leucovorin; 5-FU; Irinotecan; Gemcitabine; Nab-paclitaxel; Capecitabine,,"Astellas Pharma Global Development, Inc.",,25,2025-10-16,2027-11-30,United States,No,https://clinicaltrials.gov/study/NCT07024615
NCT07033689,"Open-label, Non-randomized, Single-center Study Investigating the Feasibility, Safety, Tolerability and Efficacy of Suizenji in Unresectable Pancreatic Ductal Adenocarcinoma Patients",Early Phase 1,Not yet recruiting,Interventional,Pancreatic Cancer,Suizenji (an ultrasound-guided HIFU therapy system); Nal-IRI/FL; mFOLFIRINOX adjuvant chemotherapy; Gem/nab-PTX,,SONIRE Therapeutics Inc.,,10,2025-12-01,2027-03-01,United States,No,https://clinicaltrials.gov/study/NCT07033689
NCT07043270,24BRO681 : Neoadjuvant Therapy With Alternating Gemcitabine Plus Nab-Paclitaxel and mFOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial,Phase 2,Recruiting,Interventional,Pancreas Adenocarcinoma,Nab-paclitaxel + Gemcitabine; modified FOLFIRINOX (mFOLFIRINOX),,Dartmouth-Hitchcock Medical Center,,35,2025-09-29,2029-07-01,United States,No,https://clinicaltrials.gov/study/NCT07043270
NCT07047807,PDAC-PATHWAYS: A Digital Informational and Supportive Care App for Patients Initiating Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma,Not Applicable,Not yet recruiting,Interventional,PDAC - Pancreatic Ductal Adenocarcinoma,PDAC-PATHWAYS; Usual Care,,Massachusetts General Hospital,United States Department of Defense,50,2025-09-05,2027-08-05,United States,No,https://clinicaltrials.gov/study/NCT07047807
NCT07090499,A Phase 1 Open-label Study to Investigate PF-08046876 in Adult Participants With Advanced Solid Tumors.,Phase 1,Recruiting,Interventional,"Advanced/Metastatic Solid Tumors; Bladder Cancer; Urothelial Carcinoma; Advanced Non-Small Cell Lung Cancer; Carcinoma, Non Small Cell Lung; Carcinoma, Squamous Cell of Head and Neck; Head and Neck Cancer; Esophageal Cancer; Gastroesophageal Junction Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Esophageal Adenocarcinoma; Pancreatic Adenocarcinoma; Pancreatic Cancer",PF-08046876,,Pfizer,,310,2025-08-20,2029-07-08,Canada; Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT07090499
NCT07094204,A Phase 1 Study of ASP5834 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS Mutations or KRAS Amplifications,Phase 1,Recruiting,Interventional,Solid Tumor; Non-Small-Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma; Colorectal Cancer,ASP5834; panitumumab,,Astellas Pharma Inc,,364,2025-07-25,2029-04-30,United States,No,https://clinicaltrials.gov/study/NCT07094204
NCT07118176,PET Imaging Study of 68Ga-FAPI-46 Biodistribution in Cancer Patients,Phase 1,Recruiting,Interventional,Anal Carcinoma; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Cholangiocarcinoma; Colorectal Carcinoma; Esophageal Carcinoma; Gastric Carcinoma; Head and Neck Carcinoma; Hematopoietic and Lymphatic System Neoplasm; Hepatocellular Carcinoma; Lung Carcinoma; Malignant Adrenal Gland Neoplasm; Malignant Brain Neoplasm; Malignant Neoplasm of Unknown Primary; Malignant Solid Neoplasm; Malignant Testicular Neoplasm; Malignant Uterine Neoplasm; Neuroendocrine Neoplasm; Ovarian Carcinoma; Pancreatic Carcinoma; Penile Carcinoma; Pleural Carcinomatosis; Primary Peritoneal Carcinoma; Prostate Carcinoma; Salivary Gland Carcinoma; Sarcoma; Skin Carcinoma; Solitary Fibrous Tumor; Thymus Carcinoma; Thyroid Gland Carcinoma; Thyroid Gland Medullary Carcinoma; Urothelial Carcinoma; Vaginal Carcinoma,Computed Tomography; Fludeoxyglucose F-18; Gallium Ga 68 FAPi-46; Positron Emission Tomography,,Jonsson Comprehensive Cancer Center,,30,2025-08-01,2027-09-07,United States,No,https://clinicaltrials.gov/study/NCT07118176
NCT07120295,Prospective Multicenter Clinical Performance Study of a Single-use Large Channel Digital Pancreaticobiliary Scope (DPS) With Compatible Accessories,Phase 4,Recruiting,Interventional,Bile Duct Adenocarcinoma; Bile Duct Carcinoma,Dragonfly™ Digital Pancreaticobiliary System,,"University of Colorado, Denver",Dragonfly Endoscopy Inc,75,2025-08-11,2028-12-05,United States,No,https://clinicaltrials.gov/study/NCT07120295
NCT07141706,"A Phase 1a/1b, Multicenter, Open-Label, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1317 in Participants With Selected Advanced/Metastatic Solid Tumors",Phase 1,Recruiting,Interventional,Advanced/Metastatic Solid Tumors,DB-1317,,DualityBio Inc.,,233,2025-09-23,2028-06-05,Australia; United States,No,https://clinicaltrials.gov/study/NCT07141706
NCT07145255,"A Multicenter, Open-label Phase 1/2 Dose Finding, Safety, and Pharmacokinetic Study of MBRC-201, an Antibody-drug Conjugate, in Advanced Refractory Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,"Prostate Cancer Castration-resistant Prostate Cancer; Breast Cancer; Colo-rectal Cancer; Lung Cancer (Non-Small Cell); Pancreas Cancer, Duct Cell Adenocarcinoma",ADC,,MBrace Therapeutics,,150,2025-09-03,2029-12-30,United States,No,https://clinicaltrials.gov/study/NCT07145255
NCT07202247,A Phase II Randomized Study of Interventions for Metabolic Protection Against Cardiometabolic Toxicity During Androgen Deprivation Therapy (IMPACT-ADT),Phase 2,Recruiting,Interventional,Prostate Carcinoma; Recurrent Prostate Carcinoma,Antiandrogen Therapy; Behavioral Intervention; Biospecimen Collection; Cardiac Computerized Tomographic Angiography; Computed Tomography; Electronic Health Record Review; Internet-Based Intervention; Lifestyle Counseling; Medical Device Usage and Evaluation; Nutritional Intervention; Nutritional Intervention; Questionnaire Administration; Radiation Therapy; Referral; Semaglutide; Short-Term Fasting; Tirzepatide,,City of Hope Medical Center,National Cancer Institute (NCI),60,2025-12-08,2028-04-09,United States,No,https://clinicaltrials.gov/study/NCT07202247
NCT07207707,"A Phase 1a, Open-label, Multicenter, Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB548 in Participants With Advanced Solid Malignancies With a KRAS G12D Mutation",Phase 1,Recruiting,Interventional,Solid Tumor Malignancies,KQB548,,Kumquat Biosciences Inc.,,78,2025-09-16,2027-03-05,United States,No,https://clinicaltrials.gov/study/NCT07207707
NCT07223047,"A Phase 1/2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BMS-986523 As Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Malignancies; Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC),BMS-986523; Gemcitabine; Nab-Paclitaxel; Cetuximab; Pembrolizumab,,Bristol-Myers Squibb,,252,2025-11-25,2028-10-13,Canada; Spain; United States,No,https://clinicaltrials.gov/study/NCT07223047
NCT07224802,An Exosome-based Liquid Biopsy Signature for Preoperative Identification of Occult Liver Metastasis in Patients With Pancreatic Ductal Adenocarcinoma,,Recruiting,Observational,PDAC - Pancreatic Ductal Adenocarcinoma,EXELiM assay (qRT-PCR validation); EXELiM small RNA sequencing,,City of Hope Medical Center,,400,2024-06-21,2026-06-18,United States,No,https://clinicaltrials.gov/study/NCT07224802
NCT07226154,An Exosomal miRNA Based Predictive Model for Personalized Neoadjuvant Chemotherapy Selection in Pancreatic Ductal Adenocarcinoma,,Recruiting,Observational,Pancreatic Ductal Adenocarcinoma,Small RNA sequencing; PRECEPT assay (qRT-PCR validation),,City of Hope Medical Center,,200,2024-11-15,2026-06-18,United States,No,https://clinicaltrials.gov/study/NCT07226154
NCT07270237,Development and Evaluation of Ultrasound Imaging Acquisition and Analysis Methods,Not Applicable,Recruiting,Interventional,Pancreatic Cancer; Thyroid Nodule,Multiparametric ultrasound (mpUS) imaging,,Memorial Sloan Kettering Cancer Center,,85,2025-11-24,2027-11-05,United States,No,https://clinicaltrials.gov/study/NCT07270237
NCT07282912,"Phase II Prospective, Open Label Randomized Controlled Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels",Phase 2,Not yet recruiting,Interventional,Foregut Adenocarcinoma; Esophageal Adenocarcinoma; Gastroesophageal Adenocarcinoma; Gastric Adenocarcinoma; Pancreas Adenocarcinoma; Duodenal Adenocarcinoma; Ampullary Adenocarcinoma; Gallbladder Adenocarcinoma; Intra - and Extrahepatic Cholangiocarcinoma,Sequential cytoreductive intervention; Signatera Genome ultra-sensitive ctDNA blood test,,Yale University,,54,2026-01-05,2028-06-05,United States,No,https://clinicaltrials.gov/study/NCT07282912
